ALPS Advisors
SGP icon

ALPS Advisors’s SpyGlass Pharma SGP Stock Holding History

ALPS Advisors’s Portfolio SGP Stock Details SGP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$1.15M Buy
44,302
+10,370
+31% +$255K 0.01% 643
2026
Q2 		$755K Buy
+33,932
New +$736K ﹤0.01% 782

Other funds holding SGP

Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $72.4B AUM 31.32% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 33.83% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $134B AUM 35.21% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return
Police & Firemen's Retirement System of New Jersey
Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13B AUM 35.88% 1-Year Est. Return

ALPS Advisors's SGP Position: Q3 2026 in Review

ALPS Advisors increased its SpyGlass Pharma (SGP) stake by 31% in Q3 2026, buying an estimated $255K and bringing the position to 44,302 shares worth $1.15M. The position accounts for 0.01% of the portfolio, ranked #643.

ALPS Advisors first reported a position in SGP in Q2 2026 and has held it in 2 quarters since. 26 funds tracked by Wall St. Rank hold SGP as of Q3 2026.

  • ALPS Advisors held 44,302 shares of SpyGlass Pharma worth $1.15M as of Q3 2026.
  • ALPS Advisors bought 10,370 SpyGlass Pharma shares in Q3 2026, an estimated $255K.
  • SpyGlass Pharma made up 0.01% of ALPS Advisors's portfolio in Q3 2026, its #643 holding.
  • ALPS Advisors first reported a position in SpyGlass Pharma in Q2 2026 and has held it in 2 quarters since.
  • 26 funds tracked by Wall St. Rank held SpyGlass Pharma as of Q3 2026.

Based on ALPS Advisors's 13F filing for Q3 2026, filed 3 Nov 2026.